Tiziana life sciences announces continued clinical improvements in the second patient with secondary progressive multiple sclerosis (spms) after six months of dosing with intranasal foralumab

New york, sept. 20, 2022 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the second patient (“ea2”) with non-active secondary progressive multiple sclerosis (spms) receiving intranasal foralumab has shown additional clinical improvements as measured by the expanded disability status scale (edss), a standard clinical assessment.
TLSA Ratings Summary
TLSA Quant Ranking